SynthesisJournal of general internal medicine2026
Does Intensive Therapy Targeting Modifiable Risk Factors Prevent Diabetic Neuropathy in Adults with Type 2 Diabetes? A Systematic Review and Meta-analysis of Randomized Clinical Trials.
Synthesis in Journal of general internal medicine, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundDiabetic peripheral neuropathy (DPN) is a serious complication of type 2 diabetes (T2DM). Guidelines recommend targeting modifiable risk factors for primary prevention, but their effectiveness is unclear. We conducted a systematic review and meta-analysis of randomized controlled trials (RCTs) to evaluate the efficacy of interventions targeting modifiable risk factors to prevent DPN in adults with T2D.
methodsWe searched PubMed, Embase, and ClinicalTrials.gov databases for RCTs published since 1980 investigating glycemia, lipids, blood pressure (BP), smoking cessation, lifestyle, and multifactorial interventions. Two reviewers independently screened articles; a third reviewer resolved disagreements. Meta-analysis used a random-effects model. Results are reported as odds ratios (ORs) with 95% confidence and prediction intervals.
resultsFrom 1287 identified articles, 863 underwent title/abstract screening, with 41 full-text review, yielding nine studies with extractable data. Eight had low risk of bias (Cochrane RoB 1); one had unclear risk. The glycemic control meta-analysis (n = 5) yielded OR = 0.89 (95% CI 0.66-1.19; prediction interval 0.37-2.15; I DISCUSSION: Glycemic intensity interventions may result in little to no difference in incident DPN risk. The BARI-2D drug class-specific finding and single-study evidence suggesting benefit from BP-lowering and multifactorial interventions warrant further rigorous research on incident DPN.
Indexed as
Identifiers
42831957What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.